ReviewBreast cancer research : BCR2014
Paracrine signaling in mammary gland development: what can we learn about intratumoral heterogeneity?
Review in Breast cancer research : BCR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Massively parallel functional profiling prioritizes breast cancer risk variants and implicates CCDC88C in ER-positive breast cancer.HGG advances · 2026Article
- Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies.Cancer research · 2026Article
- The Secretome of the Inductive Tooth Germ Exhibits Signals Required for Tooth Development.Bioengineering (Basel, Switzerland) · 2025Article
- Imagine beyond: recent breakthroughs and next challenges in mammary gland biology and breast cancer research.Journal of mammary gland biology and neoplasia · 2023Review
- Review
- Breast cancer diagnosis is associated with relative left ventricular hypertrophy and elevated endothelin-1 signaling.BMC cancer · 2020Article
- The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor.Disease models & mechanisms · 2019Article
- Mesenchymal Wnt/β-catenin signaling induces Wnt and BMP antagonists in dental epithelium.Organogenesis · 2019Article
- PCP4/PEP19 upregulates aromatase gene expression via CYP19A1 promoter I.1 in human breast cancer SK-BR-3 cells.Oncotarget · 2018Article
- Loss of glutaredoxin 3 impedes mammary lobuloalveolar development during pregnancy and lactation.American journal of physiology. Endocrinology and metabolism · 2017Article
- Luminal STAT5 mediates H2AX promoter activity in distinct population of basal mammary epithelial cells.Oncotarget · 2016Article
- Macrophages: Regulators of the Inflammatory Microenvironment during Mammary Gland Development and Breast Cancer.Mediators of inflammation · 2016Review
- Developmental Insights into Breast Cancer Intratumoral Heterogeneity.Trends in cancer · 2015Article
- Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer.Cancer discovery · 2015Article
- Cancer: Clonal cooperation.Nature · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Paracrine signaling mechanisms play a critical role in both normal mammary gland development and breast cancer. Dissection of these mechanisms using genetically engineered mouse models has provided significant insight into our understanding of the mechanisms that guide intratumoral heterogeneity. In the following perspective, we briefly review some of the emerging concepts in this field and emphasize why elucidation of these pathways will be important for future progress in devising new and improved combinatorial therapeutic approaches for breast and other solid cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.